Nachrichten und Videos - MALLINCKRODT PLC - Seite 2

Mallinckrodt Plan of Reorganization Confirmed by U.S. Court PR Newswire DUBLIN, Feb. 3, 2022 DUBLIN , Feb. 3, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ) (" Mallinckrodt " or the "Company") today announced that its Plan of Reorganization (the "Plan") has been confirmed by the U.S. Bankruptcy Court for the District of Delaware , paving the way for the Company to begin the next stage in its reorganization process. Mark Trudeau , President and Chief Executive Officer of Mallinckrodt ,...

Mallinckrodt Earns Top Marks Again in Human Rights Campaign Foundation's 2022 Corporate Equality Index For the sixth straight year, Mallinckrodt earns a perfect 100 on the Human Rights Campaign Foundation's annual assessment of LGBTQ+ workplace equality PR Newswire DUBLIN, Jan. 31, 2022 DUBLIN , Jan. 31, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, announced that it received a score of 100 on the Human Rights Campaign Foundation's 2022 Corporate...

Mallinckrodt Announces Enrollment of First Patient in Phase 1/2a StrataSOMA Clinical Trial of StrataGraft® (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen - dsat) for Investigating the Treatment of Full-Thickness Burns -- Company pursuing additional indication for FDA-approved product as part of clinical development program -- PR Newswire DUBLIN, Dec. 16, 2021 DUBLIN , Dec. 16, 2021 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS:MNKKQ), a global biopharmaceutical...

New Data on Patients with Cutaneous T-cell Lymphoma Treated with Extracorporeal Photopheresis from a Retrospective Study Presented at the American Society of Hematology Annual Meeting Retrospective medical chart review study assessed real world treatment patterns and outcomes PR Newswire DUBLIN, Dec. 13, 2021 DUBLIN , Dec. 13, 2021 /PRNewswire/ -- Mallinckrodt plc , (OTCMKTS: MNKKQ) a global biopharmaceutical company, today announced results of a retrospective, observational medical chart review...

The Buxton Helmsley Group, Inc. (together with certain of its affiliates and clients, “BHG” or “we”), the New York City-based investment advisor to clients with significant holdings of Mallinckrodt Plc. (“Mallinckrodt” or the “Company”) (OTC: MNKKQ) common stock, and with the backing of other various shareholders, today issued an open letter responding to the departure of the Company’s Chief Communications Officer, Ms. Brandi Robinson. The Company’s Senior Vice President of...

Mallinckrodt Presents Results from Two Retrospective Studies on Real World Characteristics and Outcomes of Patients with Hepatorenal Syndrome Type-1 (HRS-1) at The Liver Meeting Digital Experience Retrospective medical chart review studies show outcomes based on disease severity and highlight unmet treatment needs in people with HRS-1 PR Newswire DUBLIN, Nov. 12, 2021 DUBLIN , Nov. 12, 2021 /PRNewswire/ -- Mallinckrodt plc , (OTCMKTS: MNKKQ) a global biopharmaceutical company, today announced...

The Buxton Helmsley Group, Inc. (together with certain of its affiliates and clients, “BHG” or “we”), the New York City-based investment advisor to clients with significant holdings of Mallinckrodt Plc. (“Mallinckrodt” or the “Company”) (OTC: MNKKQ) common stock, and with the backing of other various shareholders, today issued an open letter responding to the resignation of the Company’s Senior Vice President of Finance, Ms. Kathy Schaefer, occurring just days after BHG filed...

Mallinckrodt Presents Results on Real World Treatment Patterns and Outcomes in Hospitalized Patients with Esophageal Variceal Hemorrhage and Liver Cirrhosis Treated with Terlipressin at the American College of Gastroenterology Annual Scientific Meeting U.K., multicenter, retrospective medical chart review study showed terlipressin is commonly prescribed for esophageal variceal hemorrhage (EVH) in real world clinical practice PR Newswire DUBLIN, Oct. 25, 2021 DUBLIN , Oct. 25, 2021 /PRNewswire/...

Mallinckrodt Reaches Settlements with the Official Committee of Opioid Related Creditors, the Official Committee of Unsecured Creditors and Second Lien Noteholders

Company to File Amended Plan of Reorganization to Incorporate Terms

Company Anticipates Commencing its Confirmation Hearing in September 2021

PR Newswire DUBLIN, Sept. 3, 2021 DUBLIN , Sept. 3, 2021 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ) (" Mallinckrodt " or the "Company") today announced that it has reached...

Mallinckrodt Announces Publication of Phase 3 STRATA2016 Study in Burns - First publication of full data set shows use of StrataGraft® (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen - dsat) eliminated autografting in 96% of burn sites treated with StrataGraft, and 83.1% of patients achieved durable wound closure of the StrataGraft treatment site without autograft by three months - - Secondary endpoint data showed cosmesis at the StrataGraft and autograft treatment...

Mallinckrodt Announces Inclusion of Acthar® Gel (Repository Corticotropin Injection) in New European Respiratory Society (ERS) Treatment Guidelines for Patients with Pulmonary Sarcoidosis -- Along with a Sarcoidosis Expert Panel Consensus Statement previously published in European Respiratory Review, the ERS guidelines support the use of Acthar Gel in the management of certain patients with symptomatic pulmonary sarcoidosis -- -- Guidelines are the first ERS-issued evidence-based clinical...

Mallinckrodt Announces U.S. FDA Approval of StrataGraft® (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen - dsat) -- First approved donor site-free alternative to autograft for deep partial-thickness burns designed to handle like an autograft and support body's own ability to heal -- -- Clinical trials of StrataGraft demonstrated autograft sparing and durable wound closure by 3 months in adults with deep partial-thickness burns, providing burn surgeons with a new...

Mallinckrodt Presents Data Evaluating Acthar® Gel (Repository Corticotropin Injection) for the Treatment of Severe Keratitis at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting ‒ Phase 4 open-label study showed clinically important improvement in the patient-reported Impact of Dry Eye on Everyday Life (IDEEL) symptom bother score, the study's primary outcome measure - PR Newswire DUBLIN, May 3, 2021 DUBLIN , May 3, 2021 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS:...

Mallinckrodt Presents Data Evaluating INOmax® (Nitric Oxide) Gas, for Inhalation in a Phase 4 Observational Registry in Neonates with Pulmonary Hypertension at the Pediatric Academic Societies (PAS) 2021 Virtual Meeting - Full results presented for Phase 4 observational registry, which ended early upon achievement of statistical significance for non-inferiority in premature neonates compared to term and near-term neonates at planned interim analysis - PR Newswire DUBLIN, April 30, 2021 DUBLIN ,...

National Association of Manufacturers Selects Mallinckrodt for Two Prestigious Manufacturing Leadership Awards -- Mallinckrodt's Specialty Generics division honored with Collaborative Innovation Leadership Award for its COVID-19 pandemic response -- -- Hobart, New York site honored for fourth consecutive year, recognized for Operational Excellence Leadership in 2021 -- PR Newswire ST. LOUIS, March 29, 2021 ST. LOUIS , March 29, 2021 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ), a global...

Mallinckrodt Announces New England Journal of Medicine Publication of Results from its Phase 3 CONFIRM Study of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1) -- CONFIRM is the largest prospective study (n=300) conducted in patients with HRS-1, a life-threatening and acute form of advanced liver disease with high unmet needs and a poor prognosis -- PR Newswire DUBLIN, March 4, 2021 DUBLIN , March 4, 2021 /PRNewswire/ -- Mallinckrodt plc , a global biopharmaceutical company,...

Mallinckrodt Provides Regulatory Update on StrataGraft® PR Newswire DUBLIN, Feb. 12, 2021 DUBLIN , Feb. 12, 2021 /PRNewswire/ -- Mallinckrodt plc , a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that it is deferring action (pending a site inspection) on the Stratatech Biologics License Application (BLA) for StrataGraft ® , an investigational allogeneic cellularized scaffold product in development for the treatment...

The Buxton Helmsley Group Announces Sufficient Shareholder Backing to Call Mallinckrodt Meeting of Shareholders, Begin Realigning Board and Management with Shareholder Interests, Renegotiate Restructuring Plan PR Newswire NEW YORK, Jan. 27, 2021 NEW YORK , Jan. 27, 2021 /PRNewswire/ -- The Mallinckrodt board and management has entirely abandoned shareholder interests, attempting to push through a Chapter 11 restructuring plan (their case pending before the U.S. District of Delaware Bankruptcy...

The Buxton Helmsley Group Announces Major Shareholder Backing to Call Mallinckrodt Meeting of Shareholders, Realign Board and Management with Shareholder Interests, Renegotiate Restructuring Plan PR Newswire NEW YORK, Jan. 20, 2021 NEW YORK , Jan. 20, 2021 /PRNewswire/ -- The Mallinckrodt board and management has entirely abandoned shareholder interests, attempting to push through a Chapter 11 restructuring plan (their case pending before the U.S. District of Delaware Bankruptcy Court) that will...

The Buxton Helmsley Group to Call Meeting of Mallinckrodt Shareholders to Realign Board and Management with Shareholder Interests, Renegotiate Restructuring Plan PR Newswire NEW YORK, Jan. 15, 2021 NEW YORK , Jan. 15, 2021 /PRNewswire/ -- The Mallinckrodt board and management has entirely abandoned shareholder interests, attempting to push through a Chapter 11 restructuring plan (their case pending before the U.S. District of Delaware Bankruptcy Court) that will extinguish all shareholder...